Allarity Therapeutics Announces Special Meeting of Stockholders on April 1, 2024
Ticker: ALLR · Form: DEF 14A · Filed: Mar 8, 2024 · CIK: 1860657
Sentiment: neutral
Topics: Proxy Statement, Special Meeting, Stockholder Vote, Equity Plan, Virtual Meeting
TL;DR
<b>Allarity Therapeutics is holding a virtual Special Meeting for stockholders on April 1, 2024, to vote on proposals including an amendment to its 2021 Plan.</b>
AI Summary
Allarity Therapeutics, Inc. (ALLR) filed a Proxy Statement (DEF 14A) with the SEC on March 8, 2024. Allarity Therapeutics, Inc. will hold a virtual Special Meeting of Stockholders on April 1, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted exclusively online via live audio webcast at https://meetnow.global/MFCDWVA. Stockholders of record as of February 21, 2024, are entitled to vote. Common Stock and Series A Convertible Preferred Stock holders will vote together as a single class on Proposal 1 (Amendment to the 2021 Plan Proposal). The company is filing a Definitive Proxy Statement (DEF 14A) on March 8, 2024.
Why It Matters
For investors and stakeholders tracking Allarity Therapeutics, Inc., this filing contains several important signals. The virtual format aims to expand stockholder access and participation in company governance. Key proposals, including an amendment to the 2021 Equity Incentive Plan, will be voted on, impacting future equity compensation.
Risk Assessment
Risk Level: low — Allarity Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for a special meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Stockholders should review the proxy materials to understand the proposals, particularly the amendment to the 2021 Plan, and vote accordingly.
Key Numbers
- April 1, 2024 — Special Meeting Date (Date of the virtual Special Meeting of Stockholders.)
- 10:00 a.m. Eastern Time — Special Meeting Time (Time of the virtual Special Meeting.)
- February 21, 2024 — Record Date (Stockholders must be of record on this date to vote.)
- Proposal 1 — Key Proposal (Amendment to the 2021 Plan.)
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant name
- April 1, 2024 (date) — Date of Special Meeting
- February 21, 2024 (date) — Record date for voting eligibility
- 2021 Plan (plan) — Proposal 1 concerns an amendment to this plan
- DEF 14A (filing) — Form type filed
- March 8, 2024 (date) — Filing date
FAQ
When did Allarity Therapeutics, Inc. file this DEF 14A?
Allarity Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 8, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Allarity Therapeutics, Inc. (ALLR).
Where can I read the original DEF 14A filing from Allarity Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Allarity Therapeutics, Inc..
What are the key takeaways from Allarity Therapeutics, Inc.'s DEF 14A?
Allarity Therapeutics, Inc. filed this DEF 14A on March 8, 2024. Key takeaways: Allarity Therapeutics, Inc. will hold a virtual Special Meeting of Stockholders on April 1, 2024, at 10:00 a.m. Eastern Time.. The meeting will be conducted exclusively online via live audio webcast at https://meetnow.global/MFCDWVA.. Stockholders of record as of February 21, 2024, are entitled to vote..
Is Allarity Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Allarity Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for a special meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading Allarity Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the proposals, particularly the amendment to the 2021 Plan, and vote accordingly. The overall sentiment from this filing is neutral.
How does Allarity Therapeutics, Inc. compare to its industry peers?
Allarity Therapeutics operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapeutic solutions.
Are there regulatory concerns for Allarity Therapeutics, Inc.?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
Risk Factors
- Proxy Statement Filing [low — regulatory]: The company is filing a Definitive Proxy Statement (DEF 14A) as required for its Special Meeting of Stockholders.
Industry Context
Allarity Therapeutics operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapeutic solutions.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
What Investors Should Do
- Review the Proxy Statement for details on the proposed amendment to the 2021 Plan.
- Attend the virtual Special Meeting on April 1, 2024, or ensure your proxy is submitted.
- Understand voting rights as a stockholder of record as of February 21, 2024.
Key Dates
- 2024-04-01: Special Meeting of Stockholders — To vote on company proposals, including amendments to the 2021 Plan.
- 2024-02-21: Record Date — Determines which stockholders are eligible to vote at the Special Meeting.
- 2024-03-08: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This filing is a DEF 14A (Definitive Proxy Statement) for a Special Meeting, distinct from routine quarterly or annual reports.
Filing Stats: 4,336 words · 17 min read · ~14 pages · Grade level 12.7 · Accepted 2024-03-07 21:45:19
Key Financial Figures
- $0.0001 — and outstanding common stock, par value $0.0001 per share, at a ratio between 1 -for-5
- $0.405 — 1d; basis using the conversion price of $0.405 and based on stated value of $1,080 sub
- $1,080 — of $0.405 and based on stated value of $1,080 subject to a beneficial ownership limit
Filing Documents
- ea0200572-02.htm (DEF 14A) — 701KB
- tallarity_logo.jpg (GRAPHIC) — 59KB
- tproxy_001.jpg (GRAPHIC) — 1601KB
- tproxy_002.jpg (GRAPHIC) — 1276KB
- tproxy_003.jpg (GRAPHIC) — 1056KB
- tproxy_004.jpg (GRAPHIC) — 853KB
- 0001174947-24-000304.txt ( ) — 7376KB
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management   22 Stockholder Proposals for the 2024 Annual Meeting of Stockholders   24 Sharing the Same Last Name and Address   26 Other Matters   26 Appendix A — Amended Allarity Therapeutics, Inc. 2021 Equity Incentive Plan   A-1 Appendix B — Reverse Stock Split Amendment   B-1 Appendix C — Form of Proxy Card   C-1 Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of Stockholders to Be Held on April 1, 2024: The Notice of the Special Meeting and Proxy Statement are electronically available at htt p://www.edocumentvi ew.com / ALLR Forward -Looking Statements. The Proxy Statement may contain “ forward -looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements other than statements of historical facts included in the Proxy Statement are forward -looking statements. In some cases, you can identify forward -looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward -looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward -looking statements express